Recent ALZN News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:30:26 PM
- Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions • PR Newswire (US) • 03/26/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:30:20 PM
- Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital • PR Newswire (US) • 03/16/2026 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2026 09:46:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:30:37 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/26/2026 10:12:52 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/26/2026 10:12:17 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/09/2026 09:30:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/09/2025 09:30:59 PM
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital • PR Newswire (US) • 11/19/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 09:30:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2025 08:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 08:51:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2025 08:30:32 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 10/04/2025 01:37:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2025 08:30:46 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/23/2025 08:30:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/10/2025 08:30:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2025 08:30:35 PM
- Alzamend Neuro to Present at the 2025 Military Health System Research Symposium • GlobeNewswire Inc. • 07/28/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2025 08:30:41 PM
- Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs • GlobeNewswire Inc. • 07/23/2025 12:00:00 PM
